See more : Thai Nippon Rubber Industry Public Co., Ltd. (TNR.BK) Income Statement Analysis – Financial Results
Complete financial analysis of Ultragenyx Pharmaceutical Inc. (RARE) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Ultragenyx Pharmaceutical Inc., a leading company in the Biotechnology industry within the Healthcare sector.
- Integral Ad Science Holding Corp. (IAS) Income Statement Analysis – Financial Results
- Collective Mining Ltd. (CNL.V) Income Statement Analysis – Financial Results
- Tung Ho Steel Enterprise Corporation (2006.TW) Income Statement Analysis – Financial Results
- Guangdong DP Co.,Ltd. (300808.SZ) Income Statement Analysis – Financial Results
- Laramide Resources Ltd. (LAM.AX) Income Statement Analysis – Financial Results
Ultragenyx Pharmaceutical Inc. (RARE)
About Ultragenyx Pharmaceutical Inc.
Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia. The company's products candidatures include DTX401, an adeno-associated virus 8 (AAV8) gene therapy clinical candidate for the treatment of patients with glycogen storage disease type Ia; DTX301, an AAV8 gene therapy for the treatment of patients with ornithine transcarbamylase; UX143, a human monoclonal antibody for the treatment of osteogenesis imperfecta; GTX-102, an antisense oligonucleotide for the treatment of Angelman syndrome; UX701, for the treatment of Wilson disease; and UX053 for the treatment of glycogen storage disease type III. Ultragenyx Pharmaceutical Inc. has collaboration and license agreement with Kyowa Kirin Co., Ltd.; Saint Louis University; Baylor Research Institute; REGENXBIO Inc.; Bayer Healthcare LLC; GeneTx; Mereo; University of Pennsylvania; Arcturus Therapeutics Holdings Inc., Solid Biosciences Inc.; and Daiichi Sankyo Co., Ltd. Ultragenyx Pharmaceutical Inc. was incorporated in 2010 and is headquartered in Novato, California.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 434.25M | 363.33M | 351.41M | 271.03M | 103.71M | 51.50M | 2.61M | 133.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 45.21M | 28.32M | 16.01M | 6.13M | 9.01M | 1.15M | 1.00K | 183.20M | 1.38M | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 389.04M | 335.01M | 335.40M | 264.90M | 94.71M | 50.35M | 2.61M | -183.07M | -1.38M | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit Ratio | 89.59% | 92.21% | 95.44% | 97.74% | 91.31% | 97.77% | 99.96% | -137,647.37% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 648.45M | 705.79M | 497.15M | 412.08M | 357.36M | 294.00M | 231.64M | 183.20M | 114.74M | 45.97M | 27.83M | 12.64M | 4.72M |
| General & Administrative | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 127.72M | 99.91M | 64.94M | 33.00M | 10.81M | 4.45M | 3.34M | 1.84M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 309.80M | 278.14M | 219.98M | 182.93M | 161.52M | 127.72M | 99.91M | 64.94M | 33.00M | 10.81M | 4.45M | 3.34M | 1.84M |
| Other Expenses | 0.00 | 9.51M | 241.00K | 7.65M | 12.45M | 3.95M | 10.60M | 2.17M | -200.00K | -3.02M | -3.01M | -350.00K | -22.00K |
| Operating Expenses | 958.25M | 983.93M | 717.14M | 595.02M | 518.88M | 421.72M | 331.55M | 248.14M | 147.74M | 56.78M | 32.28M | 15.99M | 6.56M |
| Cost & Expenses | 1.00B | 1.01B | 733.14M | 601.15M | 527.89M | 422.87M | 331.55M | 248.14M | 147.74M | 56.78M | 32.28M | 15.99M | 6.56M |
| Interest Income | 26.69M | 11.07M | 1.93M | 7.04M | 13.24M | 9.54M | 4.07M | 3.79M | 2.32M | 608.00K | 216.00K | 1.00K | 4.00K |
| Interest Expense | 66.00M | 43.02M | 29.42M | 33.29M | 1.14M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 270.00K |
| Depreciation & Amortization | 26.01M | 18.20M | 13.24M | 12.26M | 8.54M | 19.54M | 5.83M | 3.42M | 1.38M | 684.00K | 444.00K | 313.00K | 34.00K |
| EBITDA | -516.45M | -640.51M | -410.32M | -139.81M | -389.77M | -177.56M | -312.51M | -244.58M | -146.35M | -56.09M | -34.63M | -16.02M | -6.55M |
| EBITDA Ratio | -118.93% | -175.99% | -108.56% | -118.98% | -396.98% | -1,051.94% | -12,593.49% | -186,471.43% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -569.21M | -648.92M | -381.74M | -330.12M | -424.17M | -371.37M | -328.94M | -248.01M | -147.74M | -56.78M | -32.28M | -15.99M | -6.56M |
| Operating Income Ratio | -131.08% | -178.60% | -108.63% | -121.80% | -408.98% | -721.18% | -12,593.49% | -186,471.43% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | -39.26M | -52.81M | -71.24M | 144.76M | 24.73M | 174.28M | 10.60M | 2.17M | 2.12M | -3.02M | -2.79M | -349.00K | -288.00K |
| Income Before Tax | -608.46M | -701.73M | -452.98M | -185.36M | -399.44M | -197.10M | -318.34M | -245.84M | -145.62M | -59.80M | -35.07M | -16.33M | -6.85M |
| Income Before Tax Ratio | -140.12% | -193.14% | -128.91% | -68.39% | -385.14% | -382.75% | -12,187.52% | -184,841.35% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | -1.83M | 5.70M | 1.04M | 1.21M | 3.28M | 514.00K | -16.20M | 35.00K | -2.32M | -684.00K | -3.01M | -350.00K | 248.00K |
| Net Income | -606.64M | -707.42M | -454.03M | -186.57M | -402.73M | -197.61M | -302.14M | -245.87M | -145.62M | -59.80M | -35.07M | -16.33M | -6.85M |
| Net Income Ratio | -139.70% | -194.71% | -129.20% | -68.84% | -388.31% | -383.75% | -11,567.34% | -184,867.67% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -8.25 | -10.12 | -6.70 | -3.07 | -7.12 | -3.97 | -7.12 | -6.21 | -3.96 | -2.08 | -1.21 | -0.71 | -0.30 |
| EPS Diluted | -8.25 | -10.12 | -6.70 | -3.07 | -7.12 | -3.97 | -7.12 | -6.21 | -3.96 | -2.08 | -1.21 | -0.71 | -0.30 |
| Weighted Avg Shares Out | 73.54M | 69.91M | 67.80M | 60.85M | 56.58M | 49.78M | 42.45M | 39.59M | 36.78M | 28.76M | 29.06M | 23.06M | 23.06M |
| Weighted Avg Shares Out (Dil) | 73.54M | 69.91M | 67.80M | 60.85M | 56.58M | 49.78M | 42.45M | 39.59M | 36.78M | 28.76M | 29.06M | 23.06M | 23.06M |
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Ultragenyx (RARE) Q4 Loss Narrower Than Expected, Revenues Beat
Ultragenyx Pharmaceutical, Inc. (RARE) Q4 2023 Earnings Call Transcript
Compared to Estimates, Ultragenyx (RARE) Q4 Earnings: A Look at Key Metrics
Ultragenyx (RARE) Reports Q4 Loss, Tops Revenue Estimates
Ultragenyx Reports Fourth Quarter and Full Year 2023 Financial Results and Corporate Update
What Analyst Projections for Key Metrics Reveal About Ultragenyx (RARE) Q4 Earnings
Ultragenyx to Host Conference Call for Fourth Quarter and Full-Year 2023 Financial Results and Corporate Update
Ultragenyx (RARE) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
Ultragenyx Announces Data Demonstrating Treatment with UX111 Results in Significant Reduction in Heparan Sulfate Exposure in Cerebrospinal Fluid Correlated with Improved Long-term Cognitive Function in Patients with Sanfilippo Syndrome Type A (MPS IIIA)
Source: https://incomestatements.info
Category: Stock Reports